Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance

Science Translational Medicine
Yu ShiShideng Bao

Abstract

Glioblastoma (GBM) is the most lethal primary brain tumor and is highly resistant to current treatments. GBM harbors glioma stem cells (GSCs) that not only initiate and maintain malignant growth but also promote therapeutic resistance including radioresistance. Thus, targeting GSCs is critical for overcoming the resistance to improve GBM treatment. Because the bone marrow and X-linked (BMX) nonreceptor tyrosine kinase is preferentially up-regulated in GSCs relative to nonstem tumor cells and the BMX-mediated activation of the signal transducer and activator of transcription 3 (STAT3) is required for maintaining GSC self-renewal and tumorigenic potential, pharmacological inhibition of BMX may suppress GBM growth and reduce therapeutic resistance. We demonstrate that BMX inhibition by ibrutinib potently disrupts GSCs, suppresses GBM malignant growth, and effectively combines with radiotherapy. Ibrutinib markedly disrupts the BMX-mediated STAT3 activation in GSCs but shows minimal effect on neural progenitor cells (NPCs) lacking BMX expression. Mechanistically, BMX bypasses the suppressor of cytokine signaling 3 (SOCS3)-mediated inhibition of Janus kinase 2 (JAK2), whereas NPCs dampen the JAK2-mediated STAT3 activation via the neg...Continue Reading

References

Aug 24, 1999·Cell·J F BrombergJ E Darnell
Nov 19, 2004·Nature·Sheila K SinghPeter B Dirks
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Feb 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Noha SemaanJean Sibilia
Oct 24, 2009·Nature Reviews. Cancer·Hua YuRichard Jove
May 7, 2010·CA: a Cancer Journal for Clinicians·Erwin G Van MeirJeffrey J Olson
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
May 18, 2012·Cancer Research·Tanja HolopainenKari Alitalo
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Mar 5, 2013·Nature Structural & Molecular Biology·Nadia J KershawJeffrey J Babon
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jun 26, 2015·Genes & Development·Justin D LathiaJeremy N Rich
Aug 1, 2015·Medical Oncology·Davide GrisafiFrancesco Scaglione
May 19, 2017·JCI Insight·Jinkyu JungJeremy N Rich
May 30, 2017·Cancer Cell·Michail S LionakisWyndham H Wilson

❮ Previous
Next ❯

Citations

Nov 13, 2018·Journal of Cellular Physiology·Masoud NajafiKeywan Mortezaee
Mar 9, 2019·International Journal of Molecular Sciences·Mozhgan Dehghan HaratiMahmoud Toulany
Nov 16, 2019·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Kai LiJing-Wei Zhang
Mar 20, 2020·Journal of Drug Targeting·Senthilkumar KalimuthuByeong-Cheol Ahn
Mar 20, 2019·Journal of Molecular Neuroscience : MN·Marienela Buendia DuqueRafael Roesler
Jun 5, 2019·Genes & Development·Ryan C GimpleJeremy N Rich
Aug 1, 2020·Frontiers in Oncology·Xuehai WangNing Yang
Sep 22, 2020·Advanced Therapeutics·O TuranE Karathanasis
Jan 6, 2021·International Journal of Molecular Sciences·Alexander OuNazanin Majd
Mar 3, 2020·Seminars in Cancer Biology·Jacqueline A BrinkmanStephen J Kron
Aug 21, 2019·Life Sciences·Masoud NajafiJamal Majidpoor
Jan 28, 2021·Cancers·Alexander OuAmy B Heimberger
Feb 1, 2020·Trends in Biochemical Sciences·Annelies BogaertKris Gevaert
Feb 26, 2021·Biochemical and Biophysical Research Communications·Zhiping LiuChunhua Li
May 29, 2021·Frontiers in Cell and Developmental Biology·Kun LiuCuiping Yang
Jul 1, 2021·Oncology Letters·Yuying WuXinhua Zhang
Aug 13, 2021·Frontiers in Oncology·Giuliana CataraDaniela Spano
Aug 25, 2021·Cancer Cell International·Zheng BianXiaolu Zhang
Sep 8, 2021·Journal of Experimental & Clinical Cancer Research : CR·Hyunkoo KangBuHyun Youn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.